World Health Organization Raises Warning Over Acute Scarcity of Obesity Injections
Less than one in 10 individuals eligible to benefit from weight-loss injections including Wegovy have access to them, warns the WHO as it issues its inaugural advice on the therapies.
Given over a billion individuals worldwide currently obese, it is calling for more widespread and fairer availability to these injectable treatments.
According to estimates, more than two billion could be obese by 2030 if no action is taken.
"The new guidelines acknowledges that excess weight is a chronic disease that can be treated with thorough and lifelong treatment," remarked its chief Tedros Adhanom Ghebreyesus.
High costs, limited production capacity, and supply-chain constraints are key obstacles to broad availability to the jabs that can aid individuals in losing significant weight, notes the organization.
Skinny Jab Supply Crisis
Despite the present best projected case, the manufacturing of such drugs might only reach about 100 million people – under 10% of those who need them, as stated by the WHO.
The recommendation calls on governments and firms to expand availability, via measures including patent sharing.
A patent on the active ingredient – the core component of Novo Nordisk's Wegovy – is scheduled to end in a number of countries in 2026.
How Weight-Loss Drugs Operate
GLP-1 drugs imitate a natural hormone to reduce digestion speed, curb appetite and boost feelings of fullness so people reduce food intake.
Patients usually see weight reduction in the initial weeks of commencing the weekly injections.
Studies indicates patients may put most of the weight back on within a year of stopping the treatment, because their usual hunger come back.
To be above a healthy weight elevates your likelihood for contracting medical conditions, like type 2 diabetes, heart disease, stroke, and some malignancies.
Excess weight affects people in countries worldwide and was linked to millions of deaths worldwide in 2024, according to the WHO.
